Pharvaris N.V. (PHVS)
NASDAQ: PHVS Ā· Real-Time Price Ā· USD
31.65
-0.63 (-1.95%)
Nov 18, 2026, 1:26 PM EST - Market open
Pharvaris Employees
Pharvaris had 148 employees as of June 30, 2026. The number of employees increased by 34 or 29.82% compared to the same quarter last year. That makes Pharvaris the 28,944th largest employer in the world and 3,651st in the United States.
Employees
148
Change (1Y)
34
Growth (1Y)
29.82%
Revenue / Employee
n/a
Profits / Employee
-$1,390,309
Market Cap
2.24B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 148 | 34 | 29.82% |
| Mar 31, 2026 | 134 | 15 | 12.61% |
| Dec 31, 2025 | 129 | 21 | 19.44% |
| Sep 30, 2025 | 118 | 26 | 28.26% |
| Jun 30, 2025 | 114 | 31 | 37.35% |
| Mar 31, 2025 | 119 | 36 | 43.37% |
| Dec 31, 2024 | 108 | 26 | 31.71% |
| Sep 30, 2024 | 92 | 22 | 31.43% |
| Jun 30, 2024 | 83 | 15 | 22.06% |
| Mar 31, 2024 | 83 | 17 | 25.76% |
| Dec 31, 2023 | 82 | 17 | 26.15% |
| Sep 30, 2023 | 70 | 14 | 25.00% |
| Jun 30, 2023 | 68 | 21 | 44.68% |
| Mar 31, 2023 | 66 | 25 | 60.98% |
| Dec 31, 2022 | 65 | 31 | 91.18% |
| Sep 30, 2022 | 56 | 39 | 229.41% |
| Jun 30, 2022 | 47 | 30 | 176.47% |
| Mar 31, 2022 | 41 | 27 | 192.86% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Arcus Biosciences | 601 |
| Beam Therapeutics | 557 |
| Replimune Group | 465 |
| Biohaven | 274 |
| Immunome | 267 |
| Celldex Therapeutics | 198 |
| Lakefront Biotherapeutics NV | 196 |
| Septerna | 134 |
PHVS News
- 6 days ago - Pharvaris says Chapter-3 met primary, secondary efficacy endpoints - TheFly
- 6 days ago - Pharvaris Presents Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting - GlobeNewsWire
- 6 days ago - Pharvaris reports Q3 EPS (EUR0.67) vs. (EUR0.60) last year - TheFly
- 6 days ago - Pharvaris Reports Third Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 9 days ago - Pharvaris Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 20 days ago - Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting - GlobeNewsWire
- 26 days ago - Pharvaris upgraded to Buy at BofA after āvaluation resetā - TheFly
- 26 days ago - Pharvaris upgraded to Buy from Neutral at BofA - TheFly